title: Potential clinical role of telomere length in human glioblastoma.
abstract: Glioblastoma Multiforme (GBM) is the most common and lethal of human primary central nervous system (CNS) tumors. Due to the tumour's intrinsic clinical and molecular heterogeneity, choice of initial treatment, prediction of survival, stratification of patients, prediction and monitoring of response to therapy, represent some of the greatest challenges in the management of GBM patients. Patients, despite optimal surgery, radiation and chemotherapy, still have a median survival of 14-16 months. A reason for this dismal prognosis is because of the relative inaccuracy of current prognostic markers, so far based on clinical or pathological variables. Molecular markers that effectively predict response to therapy and survival outcomes are limited. Consequently, there is a strong need to develop novel and independent markers of prognosis. Ideal biomarkers for solid tumors would serve one or more important functions. Telomeres, guanine-rich tandem DNA repeats of the chromosomal end, provide chromosomal stability, regulates important cellular processes, and seem to be implicated in human carcinogenesis. Recently, telomeres have been shown either to be associated with clinical markers of disease progression or to be independent markers of cancer prognosis in solid tumours, including GBM. Nevertheless, a corresponding comprehensive discussion of these promising developments in brain tumours has not yet been available in the literature. Therefore, here we reviewed studies focused on the assessment of telomeric length in brain tumours with the aim to emphasized those findings indicating a potential clinical role of telomeres in GBM. With the aim to enhance the awareness of the potential clinical role of telomeres' length information in GBM, using a southern blot analysis, telomeric length in excised tumour samples was analyzed. Moreover, an attempt to correlated telomere length with patients' overall survival, was also performed. The findings here reviewed shows some contradictory results, due to different tissues used as controls, but mainly to cellular and molecular heterogeneity in GBMs that drive molecular mechanisms controlling telomere length, included telomerase and Alternative Lengthening of Telomeres (ALT), through multiple mechanisms. However, overall these studies, including our own, are consistent with the hypothesis that GBMs' telomeres were always shorter when compared with Normal Brain Tissue (NBT), and together with higher telomerase activity seem to be associated with malignancy and poor outcome; while tumours with ALT phenotype have longer telomeres, "less malignant" behaviour and better prognosis. We conclude that, although not entirely consistent in the type of telomere alteration, i.e., attrition vs. elongation, and unclear on the underlying mechanisms, multiple studies in brain tumours have shown that telomere dysfunctions are associated with parameters of clinical outcome in patients with GBMs and therefore will be part of novel risk assessment and prognostic modalities for patients with these still dismal disease.
authors.affiliation: Department of Neurosciences, Psychiatric and Anesthesiological Sciences, University of Messina School of Medicine, Messina, Italy.
authors.forename: D
authors.initials: D
authors.lastname: La Torre
authors.forename: M
authors.initials: M
authors.lastname: Aguennouz
authors.forename: A
authors.initials: A
authors.lastname: Conti
authors.forename: M
authors.initials: M
authors.lastname: Giusa
authors.forename: G
authors.initials: G
authors.lastname: Raffa
authors.forename: R V
authors.initials: RV
authors.lastname: Abbritti
authors.forename: A
authors.initials: A
authors.lastname: Germano'
authors.forename: F F
authors.initials: FF
authors.lastname: Angileri
keywords: Brain tumor; Glioblastoma multiforme; Glioma; Telomere length; prognostic marker
references.citation: Neoplasia. 2006 Feb;8(2):136-42
references.pmid: 16611406
references.citation: Mol Cancer Ther. 2010 Sep;9(9):2568-81
references.pmid: 20643785
references.citation: Science. 1994 Dec 23;266(5193):2011-5
references.pmid: 7605428
references.citation: Cancer Res. 2003 Sep 15;63(18):5821-8
references.pmid: 14522905
references.citation: Science. 2009 Jun 26;324(5935):1670-3
references.pmid: 19556499
references.citation: Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
references.pmid: 9422557
references.citation: Clin Lab Med. 1999 Dec;19(4):833-47
references.pmid: 10572718
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83
references.pmid: 14645703
references.citation: Cancer Res. 2004 Oct 1;64(19):7011-21
references.pmid: 15466194
references.citation: Nat Genet. 1998 Jun;19(2):182-6
references.pmid: 9620778
references.citation: Cancer Res. 1998 May 15;58(10):2117-25
references.pmid: 9605755
references.citation: Zhonghua Yi Xue Za Zhi. 1996 Aug;76(8):588-90
references.pmid: 9275471
references.citation: Neurosurgery. 2005 Apr;56(4):802-10
references.pmid: 15792519
references.citation: Biochem Biophys Res Commun. 1997 Oct 29;239(3):830-4
references.pmid: 9367854
references.citation: J Urol. 2005 Feb;173(2):610-4
references.pmid: 15643274
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63
references.pmid: 17548814
references.citation: Cancer. 2006 Feb 1;106(3):541-51
references.pmid: 16388518
references.citation: Neuro Oncol. 2008 Oct;10(5):675-89
references.pmid: 18701711
references.citation: Int J Oncol. 2000 Nov;17(5):981-9
references.pmid: 11029502
references.citation: Cell. 2001 Sep 21;106(6):661-73
references.pmid: 11572773
references.citation: Mol Cells. 2009 Jul 31;28(1):7-12
references.pmid: 19655094
references.citation: Lung Cancer. 1994 Jul;11(1-2):29-41
references.pmid: 8081703
references.citation: N Engl J Med. 2001 Jan 11;344(2):114-23
references.pmid: 11150363
references.citation: Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
references.pmid: 12629218
references.citation: Nature. 2007 Jan 4;445(7123):111-5
references.pmid: 17122771
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: Nature. 1991 Apr 18;350(6319):569-73
references.pmid: 1708110
references.citation: Neurosurgery. 1998 May;42(5):1120-4; discussion 1124-5
references.pmid: 9588558
references.citation: Cancer. 1994 Jun 15;73(12):2978-84
references.pmid: 7911069
references.citation: Clin Cancer Res. 2010 Jan 1;16(1):154-63
references.pmid: 20048334
references.citation: Nat Genet. 2003 Aug;34(4):369-76
references.pmid: 12923544
references.citation: Biotechniques. 1997 Sep;23(3):476-8, 480, 482, passim
references.pmid: 9298219
references.citation: Nat Med. 1997 Jul;3(7):730-7
references.pmid: 9212098
references.citation: Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12683-8
references.pmid: 11675499
references.citation: Breast Cancer Res Treat. 2006 Sep;99(2):193-202
references.pmid: 16752076
references.citation: Nature. 2004 Nov 18;432(7015):396-401
references.pmid: 15549107
references.citation: Genes Dev. 2005 Sep 15;19(18):2100-10
references.pmid: 16166375
references.citation: J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9
references.pmid: 11895036
references.citation: Cell. 1999 May 14;97(4):527-38
references.pmid: 10338216
references.citation: Lancet Oncol. 2009 May;10(5):459-66
references.pmid: 19269895
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8
references.pmid: 17210912
references.citation: Science. 2002 Jul 26;297(5581):565-9
references.pmid: 12142527
references.citation: Breast Cancer Res Treat. 1999 Mar;54(1):59-64
references.pmid: 10369081
references.citation: J Clin Invest. 2010 Jan;120(1):41-50
references.pmid: 20051635
references.citation: Cancer. 2003 Jul 1;98(1):110-8
references.pmid: 12833463
references.citation: Nat Rev Cancer. 2002 Nov;2(11):879-84
references.pmid: 12415258
references.citation: Trends Cell Biol. 1995 Aug;5(8):293-7
references.pmid: 14732086
references.citation: Nature. 2008 Jan 17;451(7176):345-9
references.pmid: 18202660
references.citation: Nat Rev Cancer. 2006 Jun;6(6):425-36
references.pmid: 16723989
references.citation: Hum Genet. 1993 Mar;91(2):190-2
references.pmid: 8462979
references.citation: J Neurosurg. 2000 Oct;93(4):618-25
references.pmid: 11014540
references.citation: J Cell Biol. 1999 Feb 22;144(4):589-601
references.pmid: 10037783
references.citation: Jpn J Cancer Res. 1992 Feb;83(2):159-64
references.pmid: 1555997
references.citation: Nature. 1994 Feb 17;367(6464):645-8
references.pmid: 7509044
references.citation: Clin Cancer Res. 2011 Jan 1;17(1):111-21
references.pmid: 21208905
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: Eur J Cell Biol. 2003 Sep;82(9):441-6
references.pmid: 14582532
references.citation: Hum Mol Genet. 2001 Sep 1;10(18):1953-61
references.pmid: 11555632
references.citation: Nat Med. 1997 Nov;3(11):1271-4
references.pmid: 9359704
references.citation: Head Neck. 2002 Dec;24(12):1060-7
references.pmid: 12454944
references.citation: Neurol Clin. 2007 Nov;25(4):867-90, vii
references.pmid: 17964019
references.citation: Anticancer Res. 2000 May-Jun;20(3B):2181-7
references.pmid: 10928174
references.citation: Lancet. 2003 Mar 8;361(9360):836-8
references.pmid: 12642053
references.citation: Cell. 1999 Mar 5;96(5):701-12
references.pmid: 10089885
references.citation: J Clin Oncol. 2004 May 15;22(10):1807-14
references.pmid: 15143073
references.citation: Oncol Rep. 2007 Dec;18(6):1571-6
references.pmid: 17982646
references.citation: Annu Rev Biochem. 2004;73:177-208
references.pmid: 15189140
references.citation: Br J Cancer. 2007 Apr 10;96(7):1020-4
references.pmid: 17353922
references.citation: Br J Cancer. 2010 Mar 2;102(5):789-95
references.pmid: 20104230
references.citation: Nature. 2000 Nov 2;408(6808):53-6
references.pmid: 11081503
references.citation: J Urol. 1999 Nov;162(5):1788-92
references.pmid: 10524936